ACM
JBIO

Altium Capital Management’s Jade Biosciences JBIO Stock Holding History

Altium Capital Management’s Portfolio JBIO Stock Details JBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-1,457
Closed -$846K – 101
2022
Q3 		$846K Buy
+1,457
New +$973K 0.31% 86

Other funds holding JBIO

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

Altium Capital Management's JBIO Position: Q4 2022 in Review

Altium Capital Management sold out of Jade Biosciences (JBIO) in Q4 2022, closing a stake of 1,457 shares — an estimated $846K sold.

Altium Capital Management first reported a position in JBIO in Q3 2022 and held it in 1 quarter. The position peaked at $846K in Q3 2022. 68 funds tracked by Wall St. Rank hold JBIO as of Q4 2022.

  • Altium Capital Management reported no remaining Jade Biosciences position as of Q4 2022 after selling out during the quarter.
  • Altium Capital Management sold 1,457 Jade Biosciences shares in Q4 2022, an estimated $846K.
  • Altium Capital Management first reported a position in Jade Biosciences in Q3 2022 and held it in 1 quarter.
  • Altium Capital Management's Jade Biosciences position peaked at $846K in Q3 2022.
  • 68 funds tracked by Wall St. Rank held Jade Biosciences as of Q4 2022.

Based on Altium Capital Management's 13F filing for Q4 2022, filed 14 Feb 2023.